Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula | MicrobiomeTrials← Back to trialsNCT06516653
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2025-01-13Est. Completion: 2027-08
Enrollment target: 300 participants Locations- Fresenius Vascular Care Long Beach, Long Beach, California, United States
- Sarasota Memorial Hospital, Sarasota, Florida, United States
- Grady Memorial Hospital, Atlanta, Georgia, United States
- Atlanta VA Medical Center, Decatur, Georgia, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Greenwood Leflore Hospital, Greenwood, Mississippi, United States
- Azura Surgery Center Las Vegas, Las Vegas, Nevada, United States
- Fresenius Vascular Care Columbia, Columbia, South Carolina, United States
- James E. Gardner MD, P.C., Memphis, Tennessee, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Houston Methodist Hospital, Houston, Texas, United States
- Fairlawn Surgery Center, Roanoke, Virginia, United States
Other microbiome trials you might be interested in
Hereditary Leiomyomatosis and Renal Cell CarcinomaPapillary Renal Cell CarcinomaRenal Cell CarcinomaSporadic Papillary Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating…
La Jolla, United StatesEst. completion Dec 31, 2027
Chronic Kidney Failure
This study intends to measure the ED95 of remimazolam-assisted sedation in arteriovenous fistula creation by BCD.
Contact
Hangzhou, ChinaCompleted Sep 30, 2026